In vitro activity of cefepime/zidebactam against sulbactam/durlobactam-susceptible and -resistant Acinetobacter baumannii clinical isolates
Journal of Antimicrobial Chemotherapy · 2026
DOI: 10.1093/jac/dkaf467 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Carlo Tascini und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Università degli Studi di Udine, Udine, Italy. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Azabicyclo Compounds, Anti-Bacterial Agents, Sulbactam. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: RFU.
Abstract (Originalsprache)
Objectives
To evaluate the in vitro activity of cefepime in association with a β-lactamase inhibitor (enmetazobactam) or β-lactam enhancer (BLE), zidebactam, against carbapenem-resistant Acinetobacter baumannii (CRAB) strains susceptible or resistant to sulbactam/durlobactam. Material and methods Twenty-one CRAB clinical isolates were characterized by WGS and AST to cefepime/enmetazobactam, cefepime/zidebactam and comparators was determined.
Results
Resistome analysis revealed that all CRAB carried blaOXA-23 carbapenemase genes, while blaADC-25 and blaOXA-66 β-lactamase genes were observed exclusively in sulbactam/durlobactam-resistant strains. Analysis of penicillin-binding protein genes demonstrated the presence of specific mutations within PBP3 (N392T) previously associated to the resistance to sulbactam/durlobactam. Phenotypic analysis revealed that cefepime/enmetazobactam did not exert antibacterial activity against CRAB, while cefepime/zidebactam displayed potent bactericidal activity against both sulbactam/durlobactam-susceptible and -resistant strains.
Conclusions
These results demonstrate that cefepime/zidebactam exhibited potent in vitro antibacterial activity against CRAB producing OXA carbapenemase and support its clinical use against both sulbactam/durlobactam-susceptible or -resistant isolates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Università degli Studi di Udine, Udine, Italy.
- Infectious Diseases Unit, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy.
- Department of Experimental Medicine, University of Salento, Lecce, Italy.
- Microbiology and Virology Unit, Vito Fazzi Hospital, Lecce, Italy.
- Department of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, USA.
- Department of Diagnostic and Public Health, Microbiology Section, Verona University, Verona, Italy.
ORCID-Profile: Gabriele Bianco, Paolo Gaibani
Förderung
- RFU
Zitieren
APA
Tascini, C., Bianco, G., Bonomo, R. A., & Gaibani, P. (2026). In vitro activity of cefepime/zidebactam against sulbactam/durlobactam-susceptible and -resistant Acinetobacter baumannii clinical isolates. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf467
Vancouver
Tascini C, Bianco G, Bonomo RA, Gaibani P. In vitro activity of cefepime/zidebactam against sulbactam/durlobactam-susceptible and -resistant Acinetobacter baumannii clinical isolates. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkaf467
BibTeX
@article{Tascini2026,
author = {Tascini, Carlo and Bianco, Gabriele and Bonomo, Robert A and Gaibani, Paolo},
title = {In vitro activity of cefepime/zidebactam against sulbactam/durlobactam-susceptible and -resistant Acinetobacter baumannii clinical isolates},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
doi = {10.1093/jac/dkaf467}
}
EUVIMED